Hansa Biopharma AB (publ) (STO:HNSA)
32.82
-0.44 (-1.32%)
Sep 2, 2025, 5:29 PM CET
Hansa Biopharma AB Revenue
Hansa Biopharma AB had revenue of 49.12M SEK in the quarter ending June 30, 2025, with 43.07% growth. This brings the company's revenue in the last twelve months to 196.47M, up 20.12% year-over-year. In the year 2024, Hansa Biopharma AB had annual revenue of 171.32M with 27.76% growth.
Revenue (ttm)
196.47M
Revenue Growth
+20.12%
P/S Ratio
14.16
Revenue / Employee
1.40M
Employees
135
Market Cap
2.78B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 171.32M | 37.22M | 27.76% |
Dec 31, 2023 | 134.09M | -20.43M | -13.22% |
Dec 31, 2022 | 154.53M | 120.65M | 356.12% |
Dec 31, 2021 | 33.88M | 27.78M | 455.56% |
Dec 31, 2020 | 6.10M | 2.73M | 81.27% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Swedish Orphan Biovitrum AB | 26.97B |
Sectra AB | 3.31B |
Getinge AB | 35.50B |
Camurus AB | 2.27B |
Medicover AB | 25.22B |
Asker Healthcare Group AB | 15.88B |
BioArctic AB | 1.86B |
AddLife AB | 10.44B |
Hansa Biopharma AB News
- 5 weeks ago - Hansa Biopharma announces key executive appointments to support continued growth - PRNewsWire
- 6 weeks ago - Hansa Biopharma AB (publ) 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 6 weeks ago - Hansa Biopharma AB (publ) (HNSBF) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Hansa Biopharma Reports Second Quarter and Interim January-June 2025 Financial Results - PRNewsWire
- 2 months ago - Hansa Biopharma appoints Dr Richard Philipson as Chief Medical Officer - PRNewsWire
- 2 months ago - Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London - PRNewsWire
- 2 months ago - Hansa Biopharma to attend BIO International Convention - PRNewsWire
- 3 months ago - Hansa Biopharma to Host Science Deep Dive Virtual Investor Event on Guillain-Barré Syndrome on June 16, 2025 - PRNewsWire